Hikma Pharmaceuticals PLC

Latest Results (30.09.2025):

Hikma Pharmaceuticals PLC reported its interim results for the six months ended 30 June 2025, showcasing a solid performance with a 6% increase in revenue compared to the same period in 2024. While operating profit declined due to a strong comparator and changes in product mix, the company reaffirmed its full-year 2025 guidance, highlighting robust demand and strategic initiatives that position it for continued growth in the second half of the year.

Revenue Growth

Group revenue rose by 6% in H1 2025 compared to H1 2024, driven by strong volumes across all segments and regions. Notably, Injectables revenue increased by 12%, supported by successful launches and the Xellia portfolio, while Branded revenue grew by 4% as market share expanded in the MENA region.

Operating Profit

Core operating profit decreased by 7% in H1 2025 versus H1 2024, reflecting an evolving product mix and the appreciation of the Euro. Despite this decline, Hikma expects to return to growth in the second half of the year, maintaining confidence in its strategic direction.

Shareholder Returns

Profit attributable to shareholders increased by 5%, with basic earnings per share up by 6%. Additionally, the interim dividend per share was raised by 12%, demonstrating Hikma's commitment to delivering value to its shareholders.

Strategic Initiatives

Hikma enhanced its growth prospects by increasing R&D investment by 20%, integrating the Xellia business to strengthen its Injectables and Rx segments, and broadening its product portfolio through new approvals and strategic partnerships. These initiatives underscore the company's focus on innovation and market expansion.